I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Laurent Peyrin‐Biroulet(Délégation Centre-Est), Gilles Macaigne(Institution de Lavigny), Stéphane Nancey, Franco Armelao(Ospedale Santa Chiara), Zia Mazhar, Denis Franchimont(McGill University Health Centre), Claudio Papi, Georgios Michalopoulos, Xavier Hébuterne(UCLouvain), Aurélien Amiot(Université Paris-Est Créteil), Pierre Blanc, Julien Kirchgesner(Université Paris-Est Créteil), Sebastian Shaji(Inserm), Michael Jen Jie Chu, Jean‐Marc Gornet(Hôpital Saint-Louis), Piotr Eder H, Guillaume Pineton de Chambrun, Sohail Shariq, Jean‐Marie Reimund(Hôpital d'Hautepierre), Marie Dewitte, A. S. Bell(University of Glasgow), Xavier Roblin(Centre Hospitalier Universitaire de Saint-Étienne)
Cited by 38
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Advanced LIGO
|Classical and Quantum Gravity|2015|3.5k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k